About this trial
This single center, single arm, open-label, phase 2 study will assess the safety and efficacy of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multifome (GBM) patients.
The objective of the Phase 2 study is to demonstrate that this surgical technique is safe and effective in a human cohort of patients with resected newly diagnosed AA or GBM and may improve progression-free survival (PFS) and overall survival (OS).
Eligibility criteria
Qualifiers
Subject is a male or female 18 years of age or older.
Subject is undergoing planned resection of known or suspected GBM.
Subject has a Karnofsky Performance Status (KPS) 70% or greater.
Subject has a life expectancy of at least 6 months, in the opinion of the Investigator.
Disqualifiers
Subject, if female, is pregnant or is breast feeding.
Subject has initiated chemotherapy or radiation treatment for diagnosis of or GBM.
Subject intends to participate in another clinical trial
Subject intends to undergo treatment with the Gliadel® wafer at the time of this surgery.
Trial design
Treatments tested in this trial
- Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)